Study to Evaluate the Efficacy and Safety of Ibrexafungerp in Patients With Fungal Diseases That Are Refractory to or Intolerant of Standard Antifungal Treatment

PHASE3CompletedINTERVENTIONAL
Enrollment

233

Participants

Timeline

Start Date

April 1, 2017

Primary Completion Date

August 25, 2023

Study Completion Date

August 25, 2023

Conditions
Invasive CandidiasisMucocutaneous CandidiasisCoccidioidomycosisHistoplasmosisBlastomycosisChronic Pulmonary AspergillosisAllergic Bronchopulmonary AspergillosisInvasive Pulmonary AspergillosisRecurrent Vulvovaginal CandidiasisOther Emerging Fungi
Interventions
DRUG

Ibrexafungerp

Experimental Study Drug

Trial Locations (37)

1935

FCRN Clinical Trial Centre, Three Rivers

6020

Medical University Innsbruck, Innsbruck

6525

Radboud University Medical Center, Department of Medicine Geert Grooteplein Zuid 8, Nijmegen

8036

Medical University of Graz Department of Internal Medicine, Department of Pulmology, Section for Infectious Disease and Tropical Medicine, Graz

10021

Memorial Sloan Kettering Cancer Center, New York

10065

Weill Cornell Medical College, New York

11794

Stony Brook University Medical Center, Stony Brook

15203

University of Pittsburg Medical Center, Pittsburgh

27157

Wake Forest Baptist Medical Center, Winston-Salem

27710

Duke University Medical Center, Durham

28007

Hospital General Universitario Gregorio Marañón, Madrid

30322

Emory University Hospital Midtown, Atlanta

30912

Augusta University, Augusta

45147

Universitätsklinikum Essen, Klinik für Infektiologie, Essen

46026

Hospital Universitari i Politecnic La Fe, Valencia

48109

University of Michigan, Ann Arbor

48201

Wayne State University, Detroit

50937

Universitätsklinikum Köln, Klinik I für Innere Medizin, Cologne

53705

University of Wisconsin, Madison

55455

University of Minnesota, Minneapolis

55905

Mayo Clinic, Rochester

60590

Universitätsklinikum Frankfurt, Department of Internal Medicine II, Frankfurt

63110

Washington University School of Medicine, St Louis

74800

Aga Khan University, Karachi

77030

University of Texas Health Science Center at Houston, Houston

81377

LMU Klinikum der Universität München, Medizinische Klinik und Poliklinik III, Munich

94143

University of California San Francisco, San Francisco

95817

UC Davis Medical Center, Sacramento

35294-0006

University of Alabama at Birmingham, Birmingham

02114

Massachusetts General Hospital, Boston

75390-8589

University of Texas Southwestern Medical Center Dallas, Dallas

04129

Klinikum St. Georg gGmbH Department for Infectious Disease, Tropical Medicine and Nephrology, Leipzig

0154

Johese Clinical Research, Lyttelton

0181

Into Research, Groenkloof

0002

Emmed Research, Pretoria

SW17 0RE

St. George's University of London, London

M13 9PL

The University of Manchester, Manchester

All Listed Sponsors
lead

Scynexis, Inc.

INDUSTRY

NCT03059992 - Study to Evaluate the Efficacy and Safety of Ibrexafungerp in Patients With Fungal Diseases That Are Refractory to or Intolerant of Standard Antifungal Treatment | Biotech Hunter | Biotech Hunter